Last reviewed · How we verify
Retpamulin Ointment, 1%
Retpamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.
Retpamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Impetigo (non-bullous and bullous forms), Secondarily infected traumatic skin lesions.
At a glance
| Generic name | Retpamulin Ointment, 1% |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Drug class | Pleuromutilin antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Retpamulin is a pleuromutilin antibiotic that selectively targets bacterial ribosomes, specifically the 50S subunit, to inhibit protein synthesis. This mechanism is bacteriostatic, stopping bacterial growth rather than directly killing the organisms. The drug has selective activity against gram-positive bacteria and some gram-negative organisms, making it suitable for topical skin infections.
Approved indications
- Impetigo (non-bullous and bullous forms)
- Secondarily infected traumatic skin lesions
Common side effects
- Application site irritation
- Application site pruritus
- Contact dermatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |